BPC-157 and anxiety: what the evidence says

The short answer is that nobody knows for certain. BPC-157 has shown anxiolytic (anxiety-reducing) effects in two rat behavioural models^[1], and a 2024 review describes it as having "anxiolytic, anticonvulsive, antidepressant" activity in rodents^[2]. At the same time, a 2026 clinical review notes that unconfirmed self-reports from human users include anxiety, heart palpitations and depression among reported side effects^[3]. The animal data and the human anecdotes point in opposite directions, and no controlled human trial resolves the conflict.

What the rodent studies actually found

The most-cited study is Sikiric et al. (2001), published in Acta Pharmacologica Sinica. Researchers gave Wistar rats intraperitoneal BPC-157 at two doses: 10 micrograms per kilogram and 10 nanograms per kilogram. They then ran two standard anxiety tests. The first was the shock-probe burying test, where a rat receives a mild shock from an electrified probe and is observed for defensive burying behaviour. The second was the light/dark preference test, which measures willingness to explore an exposed, brightly lit area. Both BPC-157 doses reduced fear-related behaviour after the shock. The researchers compared the effect to diazepam (a benzodiazepine) and noted a telling difference: BPC-157 reduced anxiety without impairing shock avoidance, while diazepam-treated rats received more shocks because their overall caution was blunted^[1]. The conclusion was that BPC-157 had an anxiolytic effect, but through a mechanism distinct from classical sedative-anxiolytics.

A 2021 review by Vukojevic and colleagues at the University of Zagreb mapped the broader picture. BPC-157 modulates multiple neurotransmitter systems relevant to anxiety: it interferes with dopamine receptor blockade and supersensitivity, influences serotonin release in specific brain regions (particularly the substantia nigra), and counteracts GABA system disturbances including diazepam tolerance and withdrawal^[4]. A separate study showed BPC-157 counteracted serotonin syndrome in rats at doses as low as 10 picograms per kilogram^[5]. A 2024 review by the same Zagreb group described BPC-157 as having "anxiolytic, anticonvulsive, antidepressant" activity in rodent models, while also noting that the peptide "by itself does not induce any behavioral change" and instead functions as a modulator of disturbed systems^[2].

These findings suggest the peptide interacts with brain chemistry in ways that could plausibly affect mood. But all of this is preclinical. Rats are not people, and anxiolytic effects in a controlled laboratory setting do not guarantee the same outcome in a human dealing with chronic pain, PTSD or real-world stressors. The Zagreb group has produced most of the published BPC-157 literature, which means the findings have not been widely replicated by independent laboratories.

Why some users report the opposite

The 2026 review by Yuan et al. in the International Journal of Molecular Sciences flagged that anonymous human self-reports include anxiety and depression among side effects^[3]. The authors were careful to note these reports are unconfirmed and should be treated cautiously. They come from online communities and clinic intake forms, not from controlled observation.

Several explanations are plausible. Grey-market vials vary widely in purity and identity; a user could be injecting something that is not BPC-157 at all, or BPC-157 contaminated with bacterial endotoxin or degradation products. The nocebo effect (anxiety about injecting an unregulated peptide) is real. Individual differences in neurotransmitter baselines matter. And the dose extrapolations used by online communities have never been validated in humans, so the amount reaching the brain in a self-administering human may differ meaningfully from what worked in rats.

What we do not know

No published randomised controlled trial has measured anxiety as an outcome in humans taking BPC-157. The US Department of Defense's Operation Supplement Safety programme classifies BPC-157 as an unapproved drug and a prohibited substance^[6]. It is not approved by the FDA, EMA, MHRA or any national medicines agency for any indication. Until a human trial with validated anxiety measures (such as the GAD-7 or the Hamilton Anxiety Rating Scale) is completed, the question of whether BPC-157 helps or worsens anxiety in people has no evidence-based answer.

Where this leaves a reader considering BPC-157

If you are dealing with anxiety or PTSD, the responsible path is a conversation with a clinician who knows your history. Anxiety disorders have well-studied treatment options with documented human safety profiles. BPC-157 is not one of them. The rodent data are interesting, but "interesting in rats" and "useful in humans" are separated by years of clinical work that has not been done for this peptide.

For more on what is and is not known about this peptide, see our BPC-157 overview and the regulation pages for country-specific legal status. If you have already obtained BPC-157 and are experiencing anxiety, stop use and consult a healthcare provider.